Literature DB >> 23167572

Investigation of chiral inversion and pharmacokinetics of laevo-ornidazole by high-performance liquid chromatography.

L-L Mu1, Z-N Cheng, X Guo, X Luo, P Yu.   

Abstract

WHAT IS KNOWN AND
OBJECTIVE: Laevo-ornidazole is an enantiomer of ornidazole, a 5-nitroimidazole antimicrobial agent. It is not known whether chiral inversion of laevo-ornidazole occurs in humans. The objective of this study was to investigate the possible chiral inversion and pharmacokinetics of the drug in vivo.
METHODS: We developed a stereo-specific high-performance liquid chromatographic method for investigating chiral inversion of the drug and a standard high-performance liquid chromatography (HPLC) for the routine assay of the drug in pharmacokinetic studies. We report on the pharmacokinetics of the drug following single dose and multiple doses and investigate the effect of food in healthy volunteers. RESULTS AND DISCUSSION: There was no chiral inversion of laevo-ornidazole in vivo. In the pharmacokinetic study of the drug in healthy Chinese volunteers, food intake affected the absorption rate of laevo-ornidazole but not the extent. WHAT IS NEW AND
CONCLUSION: We present the first reported method for the chiral separation of ornidazole in human plasma. We demonstrate the absence of chiral inversion of laevo-ornidazole in vivo. Given the absence on in vivo chiral inversion, we also report and validate a simplified non-chiral method for the determination of laevo-ornidazole. We show that although food can affect the absorption rate of laevo-ornidazole, the extent was unaffected.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23167572     DOI: 10.1111/jcpt.12015

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  2 in total

1.  Quantitative and qualitative analysis of the novel antitumor 1,3,4-oxadiazole derivative (GLB) and its metabolites using HPLC-UV and UPLC-QTOF-MS.

Authors:  Pu Li; Xin Wang; Jian Li; Zhi-Yun Meng; Shu-Chun Li; Zhong-Jun Li; Ying-Yuan Lu; Hong Ren; Ya-Qing Lou; Chuang Lu; Gui-Fang Dou; Guo-Liang Zhang
Journal:  Sci Rep       Date:  2015-07-07       Impact factor: 4.379

2.  Pharmacokinetics of Levornidazole Tablet in Healthy Chinese Subjects and Proposed Dosing Regimen Based on Pharmacokinetic/Pharmacodynamic Analysis.

Authors:  Hailan Wu; Zhiqiang Wang; Yu Wang; Jicheng Yu; Yaxin Fan; Yi Li; Jingjing Wang; Guoying Cao; Beining Guo; Yuancheng Chen; Xiaofen Liu; Xingchen Bian; Jufang Wu; Hongtao Li; Xiaojie Wu; Jing Zhang
Journal:  Infect Dis Ther       Date:  2021-04-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.